Collectively, observation disclosed that TCL1b indeed functions as an Akt kinase co-activator, underlies neoplastic diseases in vivo and, therefore, possibly serves as a novel therapeutic target of human neoplastic diseases. This evidence concerns the gene TCL1B and neoplasm.